Pfizer Inc. $PFE Shares Acquired by Fideuram Intesa Sanpaolo Private Banking S.P.A.

Fideuram Intesa Sanpaolo Private Banking S.P.A. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 754.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 657,881 shares of the biopharmaceutical company’s stock after acquiring an additional 580,924 shares during the quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Pfizer were worth $18,473,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Horizon Financial Services LLC boosted its position in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. YANKCOM Partnership acquired a new position in shares of Pfizer during the 4th quarter worth approximately $28,000. HFM Investment Advisors LLC lifted its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares in the last quarter. Finally, Global Trust Asset Management LLC grew its stake in Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 650 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on PFE shares. CICC Research started coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research note on Tuesday, June 9th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a research note on Monday, June 1st. Finally, UBS Group reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Price Performance

Pfizer stock opened at $24.29 on Friday. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The firm has a market capitalization of $138.45 billion, a price-to-earnings ratio of 18.54 and a beta of 0.35. The company has a fifty day simple moving average of $25.68 and a 200-day simple moving average of $26.24. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. Pfizer’s dividend payout ratio is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.